Published in J Am Coll Cardiol on February 01, 1998
Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardiovasc Med (2001) 1.30
Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Control Trials Cardiovasc Med (2001) 1.17
Prognostic implication of cardiac troponin T increase following stent implantation. Heart (2002) 1.13
Third universal definition of myocardial infarction. Nat Rev Cardiol (2012) 1.12
Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes. Mol Med (2007) 1.07
Acute thrombosis of the sinus node artery: arrhythmological implications. Heart (2003) 0.99
Impact of percutaneous coronary intervention timing on 5-year outcome in patients with non-ST-segment elevation acute coronary syndromes. The 'wait a day' approach might be safer. Neth Heart J (2016) 0.98
Potential shift from coronary bypass surgery to percutaneous coronary intervention for multivessel disease and its economic impact in the drug-eluting stent era. Can J Cardiol (2007) 0.90
Comparison of outcomes of percutaneous coronary intervention on proximal versus non-proximal left anterior descending coronary artery, proximal left circumflex, and proximal right coronary artery: a cross-sectional study. BMC Cardiovasc Disord (2007) 0.87
Incidence of periprocedural myocardial infarction and cardiac biomarker testing after percutaneous coronary intervention in Japan: results from a multicenter registry. Heart Vessels (2012) 0.87
Safety and efficacy of bivalirudin with glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention. Indian Heart J (2012) 0.85
Safe and feasible immediate retransfer of patients to the referring hospital after acute coronary angiography and percutaneous coronary angioplasty for patients with acute coronary syndrome. Eur Heart J Acute Cardiovasc Care (2013) 0.84
Detection of coronary microembolisation by Doppler ultrasound during percutaneous coronary interventions. Heart (2005) 0.84
Myocardial protection with prophylactic oral metoprolol during coronary artery bypass grafting surgery: evaluation by troponin I. Rev Bras Cir Cardiovasc (2014) 0.84
Preprocedural statin therapy reduces the risk and extent of cardiac biomarker release following percutaneous coronary intervention. Heart Vessels (2006) 0.84
Temporal changes in circulating P-selectin, plasminogen activator inhibitor-1, magnesium, and creatine kinase after percutaneous coronary intervention. J Zhejiang Univ Sci B (2010) 0.83
One-year clinical outcomes of ultra long apollo polymer-based Paclitaxel-eluting stents in patients with complex, long coronary artery lesions. J Tehran Heart Cent (2011) 0.82
Embolic protection devices. Heart (2003) 0.81
Periprocedural myocardial injury in chronic total occlusion percutaneous interventions: a systematic cardiac biomarker evaluation study. JACC Cardiovasc Interv (2013) 0.81
Actual Role of Platelet Glycoprotein IIb/IIIa Receptor Inhibitors as Adjunctive Pharmacological Therapy to Primary Angioplasty in Acute Myocardial Infarction: In the Light of Recent Randomized Trials and Observational Studies with Bivalirudin. Open Cardiovasc Med J (2010) 0.80
The assessment of Shin's method for the prediction of creatinine kinase-MB elevation after percutaneous coronary intervention: an intravascular ultrasound study. Int J Cardiovasc Imaging (2010) 0.80
Platelet-larger cell ratio and the risk of periprocedural myocardial infarction after percutaneous coronary revascularization. Heart Vessels (2013) 0.80
High-dose atorvastatin pretreatment could diminishes microvascular impairment in patients undergoing elective percutaneous coronary intervention. J Geriatr Cardiol (2013) 0.79
Short- and long-term outcomes of percutaneous coronary intervention in patients with low, intermediate and high ejection fraction. Cardiovasc J Afr (2008) 0.79
Same-day transfer of patients with unstable angina and non-ST segment elevation myocardial infarction back to their referring hospital after angioplasty. Can J Cardiol (2006) 0.79
Distal embolic protection during percutaneous intervention of aorto-coronary venous bypass grafts: the FIRST Trial. Clin Res Cardiol (2007) 0.78
Intermediate and high peri-operative cardiac enzyme release following isolated coronary artery bypass surgery are independently associated with higher one-year mortality. J Cardiothorac Surg (2006) 0.77
Increased risk of heart failure as a consequence of perioperative myocardial injury after coronary artery bypass grafting. Heart (2005) 0.77
Distal protection devices during percutaneous coronary and carotid interventions. Curr Control Trials Cardiovasc Med (2001) 0.77
Effects of intravenous diltiazem in a rat model of experimental coronary thrombotic microembolism. Exp Ther Med (2013) 0.77
Intracoronary adenosine to prevent myonecrosis in patients with stable angina undergoing percutaneous interventions: a double-blinded randomized controlled trial. J Tehran Heart Cent (2013) 0.76
Rise of serum troponin levels following uncomplicated elective percutaneous coronary interventions in patients without clinical and procedural signs suggestive of myocardial necrosis. Postepy Kardiol Interwencyjnej (2016) 0.76
Magnetic resonance imaging and multi-detector computed tomography assessment of extracellular compartment in ischemic and non-ischemic myocardial pathologies. World J Cardiol (2014) 0.75
A correlation between acute kidney injury and myonecrosis after scheduled percutaneous coronary intervention. J Zhejiang Univ Sci B (2013) 0.75
Pharmacological prevention of peri-, and post-procedural myocardial injury in percutaneous coronary intervention. Curr Cardiol Rev (2008) 0.75
Debate: When should we intervene in unstable angina - Time for an old look? Curr Control Trials Cardiovasc Med (2000) 0.75
Treating percutaneous coronary intervention-related myocardial injury with metformin. Cardiology (2013) 0.75
Suppression of Myocardial Injury Markers following Percutaneous Coronary Interventions by Pre-treatment with Carvedilol. Int Cardiovasc Res J (2012) 0.75
Diagnostic and prognostic value of minor elevated cardiac troponin levels for percutaneous coronary intervention-related myocardial injury: a prospective, single-center and double-blind study. J Biomed Res (2014) 0.75
Role of endothelin in microvascular dysfunction following percutaneous coronary intervention for non-ST elevation acute coronary syndromes: a single-centre randomised controlled trial. Open Heart (2016) 0.75
Prospective validation of the Dante Pazzanese risk score in non-ST-segment elevation acute coronary syndrome. Arq Bras Cardiol (2013) 0.75
Incidence and impact on prognosis of peri-procedural myocardial infarction in 2760 elective patients with stable angina pectoris in a historical prospective follow-up study. BMC Cardiovasc Disord (2016) 0.75
Off-pump coronary artery bypass surgery compared with stent implantation and on-pump bypass surgery: clinical outcome and cost-effectiveness at one year. Neth Heart J (2005) 0.75
In-hospital and mid-term adverse clinical outcomes of a direct stenting strategy versus stenting after pre-dilatation for the treatment of coronary artery lesions. Cardiovasc J Afr (2008) 0.75
Elevated preoperative HMGB1 as predictor of myocardial injury post-percutaneous coronary intervention. Medicine (Baltimore) (2016) 0.75
The effects of prior calcium channel blocker therapy on creatine kinase-MB levels after percutaneous coronary interventions. Vasc Health Risk Manag (2008) 0.75
Embolization after percutaneous coronary intervention in acute coronary syndrome. Saphenous vein grafts versus native coronary arteries. Herz (2014) 0.75
Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA (2001) 13.93
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 9.16
Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet (1992) 7.22
Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med (1994) 6.78
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med (1996) 5.94
Functional role of human immunodeficiency virus type 1 vpu. Proc Natl Acad Sci U S A (1989) 5.72
Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med (2000) 5.43
A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med (1998) 4.68
Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med (1999) 4.53
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med (1995) 4.29
Cardiac surgery report cards: comprehensive review and statistical critique. Ann Thorac Surg (2001) 4.26
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med (2000) 4.19
Short-term effects of carbon monoxide exposure on the exercise performance of subjects with coronary artery disease. N Engl J Med (1989) 4.02
Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation (1998) 3.92
Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation (1996) 3.82
Association between myeloperoxidase levels and risk of coronary artery disease. JAMA (2001) 3.74
Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc Natl Acad Sci U S A (1993) 3.63
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation (2000) 3.61
Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation (1996) 3.58
Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation (1990) 3.49
Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med (1996) 3.40
Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation (1995) 3.38
Outmigration for coronary bypass surgery in an era of public dissemination of clinical outcomes. Circulation (1996) 3.32
Increased coronary perforation in the new device era. Incidence, classification, management, and outcome. Circulation (1994) 3.30
Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation (1996) 3.28
Clinical, angiographic, and hemodynamic findings in patients with anomalous origin of the coronary arteries. Circulation (1976) 3.11
Cocaine-induced coronary-artery vasoconstriction. N Engl J Med (1989) 3.04
A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med (1987) 3.04
Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol (2001) 2.99
Transient asymptomatic S-T segment depression during daily activity. Am J Cardiol (1977) 2.94
Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA (1997) 2.93
Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med (1997) 2.86
Idiopathic short QT interval: a new clinical syndrome? Cardiology (2000) 2.85
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med (2001) 2.83
Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med (1996) 2.83
Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet (1997) 2.80
The Women's Ischemia Syndrome Evaluation (WISE) study: protocol design, methodology and feasibility report. J Am Coll Cardiol (1999) 2.79
Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation (2001) 2.73
A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. N Engl J Med (1990) 2.73
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest (2001) 2.72
Can coronary flow parameters after stent placement predict restenosis? Cathet Cardiovasc Diagn (1995) 2.69
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. Eur Heart J (2004) 2.67
Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation (2001) 2.66
Mutational analysis of the 5' non-coding region of human immunodeficiency virus type 1: effects of secondary structure on translation. EMBO J (1988) 2.65
The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J Virol (1995) 2.64
Immediate and late clinical outcomes of carotid artery stenting in patients with symptomatic and asymptomatic carotid artery stenosis: a 5-year prospective analysis. Circulation (2001) 2.60
Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med (2000) 2.57
The Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol (1999) 2.56
Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation (1997) 2.55
Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med (2001) 2.54
Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation (1995) 2.53
Selection of patients with acute myocardial infarction for thrombolytic therapy. Ann Intern Med (1990) 2.48
The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal rabbit and the hypercholesterolemic Yucatan micropig. Circulation (1994) 2.44
Cardiogenic shock complicating acute coronary syndromes. Lancet (2000) 2.42
Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med (1993) 2.39
The Novacode criteria for classification of ECG abnormalities and their clinically significant progression and regression. J Electrocardiol (1998) 2.38
Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation (1998) 2.37
Cause of death in clinical research: time for a reassessment? J Am Coll Cardiol (1999) 2.36
Angiographic prevalence of high-risk coronary artery disease in patient subsets (CASS). Circulation (1981) 2.36
Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J (2001) 2.30
Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. Heart (2009) 2.28
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. Clin Chem (1998) 2.27
A comparison of U.S. and Canadian cardiac catheterization practices in detecting severe coronary artery disease after myocardial infarction: efficiency, yield and long-term implications. J Am Coll Cardiol (1999) 2.24
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet (2001) 2.23
Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol (1999) 2.23
Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study. Am Heart J (2001) 2.22